Table S3.
Variables | Overall survival | |||
---|---|---|---|---|
Univariate analysis | Multivariate analysis | |||
HR (95% CI) | P value | HR (95% CI) | P value | |
Periostin expression in stroma (high level vs low level) | 0.561 (0.344–0.913) | 0.020 | 0.696 (0.381–1.270) | 0.237 |
Adjuvant chemotherapy (yes vs no) | 3.124 (1.809–5.395) | <0.001 | 1.543 (0.729–3.265) | 0.257 |
Serum CEA (ng/mL; ≥ 5 vs <5) | 3.071 (1.917–4.920) | <0.001 | 1.369 (0.704–2.665) | 0.355 |
Serum CA19-9 (U/mL; ≥37 vs <37) | 2.349 (1.429–3.859) | 0.001 | 1.497 (0.777–2.886) | 0.228 |
Serum CA72-4 (U/mL; ≥6.9 vs <6.9) | 1.638 (0.911–2.944) | 0.099 | 0.997 (0.520–1.911) | 0.994 |
Diameter (cm; ≥ 4 vs <4) | 3.999 (2.469–6.479) | <0.001 | 1.949 (1.014–3.746) | 0.045 |
Depth of invasion (T3+T4 vs T0+T1+T2) | 6.032 (3.331–10.922) | <0.001 | 2.162 (0.838–5.581) | 0.111 |
Lymph node involvement (yes vs no) | 4.856 (2.771–8.508) | <0.001 | 2.716 (0.980–7.523) | 0.055 |
TNM stage (III+IV vs 0+I+II) | 4.633 (2.890–7.427) | <0.001 | 0.710 (0.270–1.867) | 0.487 |
Differentiation grade (poorly vs well+moderately) | 1.249 (0.803–1.941) | 0.324 | 1.347 (0.765–2.372) | 0.302 |
Abbreviations: CA19-9, carbohydrate antigen 19-9; CA72-4, carbohydrate antigen 72-4; CEA, carcinoembryonic antigen.